Core Insights - The performance of Steris' international operations is critical for understanding its financial strength and growth potential [1][2][3] Group 1: Financial Performance - For the quarter ending September 2025, Steris reported total revenue of $1.46 billion, reflecting a year-over-year increase of 9.9% [4] - Revenue from Ireland was $27.3 million, accounting for 1.9% of total revenue, which was a surprise increase of 9.9% compared to expectations [5] - Other Foreign Revenues generated $357.8 million, constituting 24.5% of total revenue, but fell short of the projected $406.57 million by 12% [6] Group 2: Revenue Projections - Analysts anticipate that Steris will achieve revenues of $1.49 billion in the current fiscal quarter, representing an 8.7% increase year-over-year [7] - For the entire year, total revenue is forecasted to reach $5.92 billion, an improvement of 8.4% from the previous year, with expected contributions of 2.1% from Ireland and 26.5% from Other Foreign Revenues [8] Group 3: Market Context - The company's reliance on international markets presents both opportunities and risks, making it essential to monitor international revenue trends for forecasting [9] - Financial analysts are increasingly focused on international developments to refine earnings estimates, influenced by local market conditions [10]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-38848 STERIS plc (Exact name of registrant as specified in its charter) Ireland 98-145506 ...

Core Insights - STERIS reported strong Q3 2025 results, with revenues increasing nearly 10% year-over-year to $1.46 billion and adjusted earnings per share rising by 15.4% to $2.47, both exceeding analyst expectations [1] - The company raised its full-year financial outlook, projecting adjusted earnings per share in the range of $10.15 to $10.30 [1] Market Reaction - STERIS shares jumped 8.6% in the morning session, indicating that the market views the news as significant, despite the stock's historical low volatility with only four moves greater than 5% in the past year [3] - The stock has increased by 29.6% since the beginning of the year, reaching a new 52-week high at $262.29 per share [5] Industry Context - A recent national security investigation by the U.S. Commerce Department into medical equipment and devices has raised concerns about potential tariffs, which could impact the industry significantly [4] - The investigation aims to determine if imports of medical items pose a national security risk, potentially leading to new import duties that could affect supply chains and costs for major manufacturers [4]

STERIS (NYSE:STE) Q2 2026 Earnings Call November 06, 2025 09:00 AM ET Company ParticipantsDan Carestio - CEOKaren Burton - CFOJulie Winter - VP of Investor RelationsConference Call ParticipantsMichael Pollard - AnalystBrett Fishbin - AnalystMike Matson - AnalystPatrick Wood - AnalystJason Bednar - AnalystOperatorHello and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to STERIS 2Q Fiscal 2026 Earnings Conference Call. ...

STERIS (NYSE:STE) Q2 2026 Earnings Call November 06, 2025 09:00 AM ET Company ParticipantsDan Carestio - CEOJulie Winter - VP of Investor RelationsKaren Burton - CFOConference Call ParticipantsMichael Pollard - AnalystBrett Fishbin - AnalystMike Matson - AnalystPatrick Wood - AnalystJason Bednar - AnalystOperatorHello, and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to STERIS PLC 2Q Fiscal 2026 Earnings Conference ...

STERIS (NYSE:STE) Q2 2026 Earnings Call November 06, 2025 09:00 AM ET Speaker0Hello and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to STERIS 2Q Fiscal 2026 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press Star, then the number one ...

Key Takeaways STERIS' Q2 adjusted EPS rose 15.4% to $2.47, surpassing estimates and driving a 2% stock gain. STE's Q2 revenues grew 9.8% year over year to $1.46 billion, with all business segments showing growth.STERIS lifted its fiscal 2026 EPS view to $10.15-$10.30 and raised its organic growth outlook. STERIS plc (STE) reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.47, up 15.4% from the year-ago quarter’s figure. The figure surpassed the Zacks Consensus Estimate by 3.8%.The a ...

For the quarter ended September 2025, Steris (STE) reported revenue of $1.46 billion, up 9.9% over the same period last year. EPS came in at $2.47, compared to $2.14 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.43 billion, representing a surprise of +2.31%. The company delivered an EPS surprise of +3.78%, with the consensus EPS estimate being $2.38. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Steris (STE) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.38 per share. This compares to earnings of $2.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.78%. A quarter ago, it was expected that this medical products maker would post earnings of $2.32 per share when it actually produced earnings of $2.34, delivering a surprise of +0.86%.Over the last four quarters, the com ...

Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 Second Quarter DUBLIN, IRELAND - (November 5, 2025) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 second quarter ended September 30, 2025. Total revenue from continuing operations for the second quarter of fiscal 2026 increased 10% to $1.5 billion compared with $1.3 billion in the second quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for th ...